Edwards Lifesciences Corporation (EW) saw its stock price surge 7.54% in after-hours trading on Thursday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year guidance.
The medical technology company reported a robust 11.9% increase in Q2 sales, reaching $1.53 billion, surpassing the analysts' estimate of $1.49 billion. Adjusted earnings per share (EPS) came in at $0.67, beating the consensus estimate of $0.62. The company's performance was driven by strong growth across its product lines, with Transcatheter Aortic Valve Replacement (TAVR) sales rising 8.9% and Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reaching $134.5 million.
In light of these strong results, Edwards Lifesciences raised its full-year 2025 guidance. The company now expects total sales growth of 9% to 10%, projecting revenues between $5.9 billion and $6.1 billion. Additionally, the company adjusted its underlying growth rate guidance for TAVR to 6% to 7%. The positive outlook, coupled with the Q2 earnings beat, appears to have fueled investor optimism, leading to the significant after-hours stock price increase.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。